Key Factor Supporting Global PD-L1 And PIK3CA Testing Market Development in 2025: Increasing Prevalence Of Cancer Is Fueling The Growth Of The Market Due To Rising Diagnosis Rates And Growing Demand For Targeted Treatments

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the PD-L1 And PIK3CA Testing Market Size By 2025?
In the past few years, the market size for PD-L1 and PIK3CA testing has experienced rapid expansion. Anticipated to rise from $1.45 billion in 2024 to $1.67 billion in 2025, it boasts an impressive compound annual growth rate (CAGR) of 15.6%. The substantial growth during the historical period is largely due to an increase in regenerative medicine clinical trials, heightened emphasis on personalized medicine, broader academic and industry partnerships, enhanced understanding of the efficacy and safety of cell therapy, along with swift advancement and original approvals for car-t and other autologous cell therapies.

How Big Is the PD-L1 And PIK3CA Testing Market Size Expected to Grow by 2029?
Anticipated to experience swift expansion in the coming years, the market size for PD-L1 and PIK3CA testing is projected to escalate to $2.96 billion by 2029, boasting a compound annual growth rate (CAGR) of 15.3%. Factors contributing to the growth in the forecast period include the rising acceptance of personalized and precision medicine, an expanding cell and gene therapy pipeline, an uptick in clinical trials and commercial approvals, increased investment in regenerative medicine, and a surge in chronic and unusual diseases. Key trends for the forecast period incorporate the progression of bioinformatics in cellular research, amalgamation of cell therapy tracking with digital health platforms, advancements in artificial intelligence (AI) and machine learning integration, innovations in cloud-based data management systems, and the combination of wearable biosensors.

View the full report here:
https://www.thebusinessresearchcompany.com/report/pd-l1-and-pik3ca-testing-global-market-report

Which Key Market Drivers Powering PD-L1 And PIK3CA Testing Market Expansion and Growth?
The growing occurrence of cancer is predicted to drive the expansion of the PD-L1 and PIK3CA testing market. Cancer, a health condition marked by the uncontrolled proliferation and spread of abnormal cells that may penetrate surrounding tissues and possibly metastasize, has steadily increased due to lifestyle-related risks and an aging population, leading to higher diagnosis rates and the need for prompt detection and effective treatment options. PD-L1 and PIK3CA tests aid in cancer management by providing accurate diagnoses and guiding personalized medications, thereby tailoring treatment plans to each patient and enhancing treatment results. For example, the American Cancer Society, a non-profit organization based in the U.S., projected in September 2024 that the number of cancer cases among men worldwide would surge by 84% by 2029, going up from 10.3 million in 2022 to 19 million. Thus, the escalating prevalence of cancer is fueling the growth of the PD-L1 and PIK3CA testing market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28289&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the PD-L1 And PIK3CA Testing Market?
Leading businesses involved in the PD-L1 and PIK3CA testing market are emphasizing on technological advancements such as companion diagnostic integration. This technological improvement is aimed at honing therapeutic targeting, augmenting treatment efficacy, and endorsing personalized medicine methods within the field of oncology. Companion diagnostic integration indicates the use of advanced testing systems, designed synchronously with targeted medicines, which can help in identifying which patient groups would most benefit from specific treatments, according to their biomarker profiles. To illustrate, in October 2024, F. Hoffmann-La Roche AG, a biotechnology and pharmaceutical company based in Switzerland, introduced Itovebi (inavolisib) in collaboration with palbociclib and fulvestrant for adult patients who have PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer, which is resistant to endocrine treatment. Approval for this regimen was granted by the Food and Drug Administration (FDA), a federal agency in the US. The approval was based on the key Phase III INAVO120 study, wherein the regimen more than doubled the progression-free survival in comparison to using only palbociclib and fulvestrant. This hallmark denotes Roche's maiden targeted treatment for HR-positive disease and includes a companion diagnostic to pinpoint eligible patients. This constitutes a crucial improvement in precision medicine for patients who have restricted initial treatment alternatives.

What Are the Emerging Segments in the PD-L1 And PIK3CA Testing Market?
The pd-l1 and pik3ca testing market covered in this report is segmented as

1) By Test Type: Immunohistochemistry, Next-Generation Sequencing, Polymerase Chain Reaction, Other Test Types
2) By Sample Type: Tissue Samples, Liquid Biopsy Samples
3) By Distribution Channel: Direct Sales, Distributors And Resellers, Online Sales Platforms
4) By Applications: Cancer Diagnosis, Drug Development, Research, Other Applications
5) By End User: Hospitals And Clinics, Laboratories, Pharmaceutical Companies

Subsegments:
1) By Immunohistochemistry: Tissue Staining, Protein Expression Analysis, Tumor Microenvironment Assessment
2) By Next-Generation Sequencing: Whole Genome Sequencing, Targeted Gene Sequencing, Exome Sequencing, Ribonucleic Acid (RNA) Sequencing
3) By Polymerase Chain Reaction: Quantitative Polymerase Chain Reaction, Reverse Transcription Polymerase Chain Reaction, Digital Polymerase Chain Reaction
4) By Other Test Types: In Situ Hybridization (ISH), Sanger Sequencing, Flow Cytometry, Microarray-Based Assays

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=28289&type=smp

Who Are the Global Leaders in the PD-L1 And PIK3CA Testing Market?
Major companies operating in the PD-L1 and PIK3CA testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Laboratory Corporation of America Holdings (Labcorp), Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Sonic Healthcare Limited, Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Myriad Genetics Inc., NeoGenomics Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Caris Life Sciences, Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., ACCB Biotech Private Limited, EntroGen Inc.

Which are the Top Profitable Regional Markets for the PD-L1 And PIK3CA Testing Industry?
North America was the largest region in the PD-L1 and PIK3CA testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in PD-L1 and PIK3CA testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=28289

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.